Updated Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

被引：1

作者：

Morschhauser, Franck ^{[1
]}

Flinn, Ian ^{[2
]}

Advani, Ranjana H. ^{[3
]}

Diefenbach, Catherine S. ^{[4
]}

Kolibaba, Kathryn ^{[5
]}

Press, Oliver W. ^{[6
]}

Sehn, Laurie H. ^{[7
]}

Chen, Andy I. ^{[8
]}

Salles, Gilles ^{[9
]}

Tilly, Herve ^{[10
]}

Cheson, Bruce D. ^{[11
]}

Assouline, Sarit ^{[12
]}

Dreyling, Martin ^{[13
]}

Hagenbeek, Anton ^{[14
]}

Zinzani, Pier Luigi ^{[15
]}

Yalamanchili, Sreeni ^{[16
]}

Lu, Dan ^{[16
]}

Jones, Cheryl ^{[16
]}

Jones, Surai ^{[16
]}

Chu, Yu-Waye ^{[16
]}

Sharman, Jeff P. ^{[17
]}

机构：

[1] Ctr Hosp Reg Univ Lille, Lille, France

[2] Sarah Cannon Res Inst, Nashville, TN USA

[3] Stanford Univ, Sch Med, Stanford, CA 94305 USA

[4] NYU, Sch Med, New York, NY USA

[5] Northwest Canc Specialists, Vancouver, WA USA

[6] Univ Washington, Seattle, WA 98195 USA

[7] Ctr Lymphoid Canc, Vancouver, BC, Canada

[8] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[9] Ctr Hosp Lyon Sud, F-69310 Pierre Benite, France

[10] Ctr Henri Becquerel, F-76038 Rouen, France

[11] Georgetown Univ Hosp, Washington, DC 20007 USA

[12] McGill Univ, Jewish Gen Hosp, Montreal, PQ H3T 1E2, Canada

[13] Klinikum Univ Munchen Campus Grosshadern, Munich, Germany

[14] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands

[15] Univ Bologna, Bologna, Italy

[16] Genentech Inc, San Francisco, CA USA

[17] Willamette Valley Canc Inst US Oncol Res, Springfield, OR USA

来源：

BLOOD | 2014年 / 124卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[41] Phase II study of dulanermin plus rituximab in patients with relapsed follicular non-Hodgkin's lymphoma (NHL).
Belada, D.
Mayer, J.
Czuczman, M. S.
Flinn, I. W.
Durbin-Johnson, B.
Bray, G. L.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[42] Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase (Ph) Ib/II Study
Sehn, Laurie H.
Herrera, Alex F.
Matasar, Matthew J.
Kamdar, Manali
Assouline, Sarit
Hertzberg, Mark
Kim, Tae Min
Kim, Won-Seog
McMillan, Andrew
Ozcan, Muhit
Hirata, Jamie M.
Penuel, Elicia
Cheng, Ji
Ku, Grace
Flowers, Christopher R.
BLOOD, 2018, 132
[43] Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma
Herrera, Alex F.
Moskowitz, Alison J.
Bartlett, Nancy L.
Vose, Julie M.
Ramchandren, Radhakrishnan
Feldman, Tatyana A.
LaCasce, Ann S.
Ansell, Stephen M.
Moskowitz, Craig H.
Fenton, Keenan
Ogden, Carol Anne
Taft, David
Zhang, Qu
Kato, Kazunobu
Campbell, Mary
Advani, Ranjana H.
BLOOD, 2017, 130
[44] Results From a Phase 1/2 Study of Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (02) : 12 - 13
[45] A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results
Jacobsen, Eric D.
Advani, Ranjana H.
Oki, Yasuhiro
Sharman, Jeff
Horwitz, Steven M.
Forero-Torres, Andres
O'Connor, Owen A.
Shustov, Andrei R.
Siddiqi, Tanya
Grove, Laurie E.
Bartlett, Nancy L.
BLOOD, 2012, 120 (21)
[46] Phase 1 Study of MDR1 Inhibitor Plus Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma
Chen, Robert W.
Chen, Lu
Herrera, Alex F.
Mei, Matthew
McBride, Katrina
Abary, Rosie
Siddiqi, Tanya
Popplewell, Leslie
Forman, Stephen J.
Rosen, Steven T.
Kwak, Larry W.
BLOOD, 2018, 132
[47] A phase I study of rituximab and buparlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma
Bond, David A.
Huang, Ying
Christian, Beth A.
Jaglowski, Samantha
Benson, Don
Alinari, Lapo
Baiocchi, Robert A.
Cohen, Jonathon B.
Blum, Kristie A.
Maddocks, Kami J.
LEUKEMIA & LYMPHOMA, 2022, 63 (07) : 1750 - 1753
[48] Results of a Pivotal Phase 2 Study of Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma
Chen, Robert
Gopal, Ajay K.
Smith, Scott E.
Ansell, Stephen M.
Rosenblatt, Joseph D.
Klasa, Richard
Connors, Joseph M.
Engert, Andreas
Larsen, Emily K.
Kennedy, Dana A.
Sievers, Eric L.
Younes, Anas
BLOOD, 2010, 116 (21) : 128 - 129
[49] BRENTUXIMAB VEDOTIN PLUS BENDAMUSTINE AS A SALVAGE TREATMENT REGIMEN FOR PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA
LaCasce, A.
Bociek, G.
Sawas, A.
Caimi, P.
Agura, E.
Matous, J.
Ansell, S.
Crosswell, H.
Islas-Ohlmayer, M.
Behler, C.
Cheung, E.
Forero-Torres, A.
Vose, J.
O'Connor, O. A.
Josephson, N.
Advani, R.
HAEMATOLOGICA, 2016, 101 : 45 - 46
[50] Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL
Northend, Michael
Wilson, William
Osborne, Wendy
Fox, Christopher P.
Davies, Andrew J.
El-Sharkawi, Dima
Phillips, Elizabeth H.
Sim, Hau Wui
Sadullah, Shalal
Shah, Nimish
Peng, Ying Ying
Qureshi, Iman
Addada, Juanah
Mora, Rocio Figueroa
Phillips, Neil
Kuhnl, Andrea
Davies, Elizabeth
Wrench, David
McKay, Pamela
Karpha, Indrani
Cowley, Anna
Karim, Richard
Challenor, Sarah
Singh, Vikram
Burton, Cathy
Auer, Rebecca
Williams, Chris
Cunningham, Joel
Broom, Angus
Arasaretnam, Anita
Roddie, Claire
Menne, Tobias
Townsend, William
BLOOD ADVANCES, 2022, 6 (09) : 2920 - 2926

← 1 2 3 4 5 →